Tae‐Yong Kim

机构：Seoul National University Hospital · ORCID：0000-0002-3930-6766

发表论文 199 篇 · 总被引 3714 次 · h-index 35

代表论文

• ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2–Positive Gastric or Gastroesophageal Junction Adenocarcinoma (2023 · Clinical Cancer Research · 被引 85)
• Multicenter single-arm phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab (2025 · Journal of Hepatology · 被引 19)
• Blood Pb levels are associated with prostate cancer prevalence among general adult males: Linking National Cancer Registry (2002–2017) and KNHANES (2008–2017) databases of Korea (2024 · International Journal of Hygiene and Environmental Health · 被引 14)
• Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis (2024 · Journal of Liver Cancer · 被引 11)
• Therapeutic potential of BOLD-100, a GRP78 inhibitor, enhanced by ATR inhibition in pancreatic ductal adenocarcinoma (2025 · Cell Communication and Signaling · 被引 5)
• Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer (KCSG-BR15-17): A randomized, open-label, multicenter, phase II trial (2023 · European Journal of Cancer · 被引 5)